Increasing evidence shows that vasoactive intestinal peptide (VIP) in BIOCARTA_VIP_PATHWAY is highly expressed in breast cancer cells along with its receptor [33], and VIP-targeted nanomedicine is under study as therapy for breast cancer [34]. Here, VIP is linked to breast carcinoma.